Applies to droperidol: injection solution
Injection route (Solution)
Cases of QT prolongation and/or torsade de pointes, some fatal, have been reported in patients receiving droperidol at doses at or below recommended doses. All patients should undergo a 12-lead ECG prior to administration of droperidol to determine if a prolonged QT interval (i.e., QTc greater than 440 msec for males or 450 msec for females) is present. Do not administer droperidol if there is a prolonged QT interval. Droperidol is contraindicated in patients with known or suspected QT prolongation, including patients with congenital long QT syndrome. Administer droperidol with extreme caution to patients who may be at risk for development of prolonged QT syndrome, are over 65 years old, abuse alcohol, or when used concomitantly with benzodiazepines, volatile anesthetics, and IV opiates. ECG monitoring should be performed prior to treatment and continued for 2 to 3 hours after completing treatment to monitor for arrhythmias.
Along with its needed effects, droperidol may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking droperidol:
Incidence not known
Some side effects of droperidol may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
Applies to droperidol: compounding powder, injectable solution
Frequency not reported: Hypotension, irregular cardiac rhythm, mild or moderate tachycardia, QT prolongation, serious arrhythmias (e.g., torsades de pointes), ventricular tachycardia, cardiac arrest, death (some of these side effects occurred in patients with no known risk factors, and some were associated with droperidol doses at or below recommended doses)
Unexplained fever, alteration of consciousness, extrapyramidal dysfunction, autonomic instability and elevated creatine kinase are all symptoms associated with neuroleptic agents. If these symptoms develop in patients receiving droperidol therapy, immediate discontinuation of the drug is warranted.
Extrapyramidal symptoms such as acute dystonia, parkinsonism, akathisia, and oculogyric crisis have been reported in patients receiving droperidol in doses as low as 0.65 mg. In addition, cases of akathisia have been reported in patients during epidural anesthesia.
Frequency not reported: Dysphoria, drowsiness, restlessness, hyperactivity, anxiety, hallucinations, dizziness, extrapyramidal symptoms, neuroleptic malignant syndrome, confusion, nervousness, paresthesia, somnolence, tremor, akathisia, oculogyric crisis, unexplained fever, alteration of consciousness, autonomic instability
Frequency not reported: pharyngitis, rhinitis, bronchospasm, laryngospasm (reported as rare)
Frequency not reported: Anaphylaxis (uncommon)
Frequency not reported : Injection site pain
Frequency not reported: Chills and/or shivering, tongue-swelling, sweating
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Droperidol